SCOTTSDALE, Ariz., July 24 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. , today announced the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), will conduct a preclinical evaluation of ImmuneRegen’s proprietary compound Radilex(TM) for its use as a potential treatment for acute radiation syndrome (ARS). ImmuneRegen has been developing Radilex for possible use in connection with life-threatening conditions associated with ARS, including neutropenia and thrombocytopenia.
The purpose of the NIAID study is to independently evaluate the efficacy of Radilex in preventing or treating radiation sickness in an animal model. NIAID will evaluate Radilex for possible activity as a medical countermeasure for application in a radiation/nuclear emergency, including a terrorist attack. These evaluations are funded as part of the NIH Radiation/ Nuclear Countermeasures Product Development Program. The goal of this program is to both increase the U.S. government’s knowledge base and support private sector product development surrounding potential medical countermeasures.
About ImmuneRegen BioSciences, Inc.
IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company’s website at www.immuneregen.com.
Statements about the Company’s future expectations, including statements about the potential for the Company’s drug candidates, science and technology, and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company’s business, are subject to various risks and uncertainties. The Company’s actual results could differ materially from expected results as a result of a number of factors, including, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that the results of the NAID’s evaluation may prove less encouraging than current results observed by the Company in other pre-clinical studies or highlight side effects not observed in current or previous pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others set forth in the Company’s periodic report on Form 10-Q for the three months ended March 31, 2006 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company’s proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.
Contact: Jason Grimley Spelling Communications 310-477-9500
ImmuneRegen BioSciences
CONTACT: Jason Grimley of Spelling Communications, +1-310-477-9500, forImmuneRegen BioSciences
Web site: http://www.immuneregen.com/
